SecBot SecBot

AKBA drug pipeline

Akebia Therapeutics, Inc. · 4 rated drugs
$0.4490
−5.3% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±8.5%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
4
4 neutral
Phase 3 trials
2
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available since September 2014.

Auryxia ferric citrate Updated Nov 7

What to watch

Auryxia has no upcoming binary catalyst; its revenue trajectory is a steady decline driven by Teva's generic entry in March 2026. The next meaningful event for Akebia as a whole is the January 2027 expiration of Vafseo's TDAPA transitional add-on payment, which could pressure Vafseo pricing. Investors should watch Q4 2026 Auryxia revenue (expected in early March 2027) to gauge the pace of generic erosion.

Bull case
  • Auryxia remains FDA-approved for two indications (hyperphosphatemia in dialysis CKD, and iron deficiency anemia in non-dialysis CKD), providing a dual-label advantage over some phosphate binders.
  • Despite generic pressure, Auryxia still generated $20 million in Q3 2026 revenue, contributing cash flow that helps fund Akebia's transition to its next-generation product Vafseo.
  • Analyst consensus on AKBA remains bullish (10 analysts: 4 strong buy, 6 buy, 2 hold) with a mean price target of $3.92, implying roughly 820% upside from the current ~$0.40 share price.
Bear case
  • Teva launched a generic version of ferric citrate on March 11, 2026, directly competing on price and eroding Auryxia's market share rapidly.
  • Auryxia Q3 2026 net revenue fell 53% year-over-year to $20.0 million (from $42.5 million), and the company expects further declines in 2026.
  • Akebia swung to a $14.4 million net loss in Q3 2026 from a $0.5 million profit a year earlier, driven largely by Auryxia's decline.
● neutral
Impact
PhasePhase 2
Time to marketEbribafusp is in Phase 2 testing with initial data expected in 2027. If Phase 2 results are positive, Phase 3 trials would be needed before any regulatory filing, putting potential approval several years away (likely 2029 or later under an optimistic scenario).

ebribafusp alfa Updated Nov 7

What to watch

The next catalyst is initial Phase 2 basket trial data, expected in 2027 (no specific month announced). Positive data would validate ebribafusp's tissue-targeted complement inhibition approach across three rare kidney diseases and could significantly increase the asset's value. Negative or equivocal data would likely reduce the pipeline's perceived value, though Akebia's commercial product Vafseo provides a revenue floor that limits downside relative to a pure single-asset developer.

Bull case
  • Ebribafusp's tissue-targeted mechanism (delivering factor H locally to C3d deposits without systemic complement suppression) could offer a safety advantage over systemic complement inhibitors, potentially reducing serious infection risk.
  • Phase 1 data in healthy volunteers showed the drug was generally well-tolerated with minimal anti-drug antibodies, and weekly 450 mg SC dosing achieved desired exposures for predicted tissue complement inhibition.
  • Akebia acquired global rights from Q32 Bio for a modest $7M upfront plus up to $12M in milestones, giving it a potentially high-upside pipeline asset at low cost.
Bear case
  • The Phase 2 basket trial is early-stage (30 patients, open-label) and initial data is not expected until 2027, meaning no near-term catalyst to drive the stock.
  • The complement inhibitor space for IgA nephropathy is increasingly crowded: iptacopan (Novartis) is already approved, and other competitors like ravulizumab and sefaxersen are in development, raising the bar for differentiation.
  • Akebia's stock trades near $0.40, well below the Nasdaq minimum bid price of $1.00, and the company received a Nasdaq deficiency notice in October 2026, creating potential delisting risk.
● neutral
Impact
PhaseApproved by FDA (Phase 3b TIW-dosing study ongoing)
Time to marketAlready on the market (FDA approved March 27, 2024; commercial launch January 2025)

Vafseo Updated Jun 30

What to watch

Watch Q4 2026 for Phase 3b TIW-dosing topline data, positive results could unlock label expansion for three-times-weekly dosing, a commercial accelerator. The bigger overhang is the stalled non-dialysis expansion path (VALOR terminated Oct 2025), which caps the addressable market. Monitor quarterly Vafseo net revenue growth and whether Vafseo can offset the Auryxia generic erosion (Teva launched generic March 2026).

Bull case
  • Vafseo is an oral alternative to injectable ESAs (the $1B+ dialysis anemia standard of care), offering convenience and a new mechanism, early real-world adoption shows rapid patient growth (60% increase in Q1 2026 vs Q4 2025) and ~1,025 prescribers as of Q1 2026
  • VOICE trial interim analysis (June 30, 2026) met stopping criteria, Vafseo showed a statistically significant reduction in hospitalizations vs. ESAs with a win odds of 1.16, a powerful real-world evidence point that could drive formulary wins and physician adoption
  • Prescribing access expanded to cover ~275,000 dialysis patients (~100% of U.S. dialysis centers) through contracts with DaVita, Fresenius, DCI, and IRC, positioning Vafseo for continued share gains
Bear case
  • The non-dialysis expansion path (VALOR trial) was terminated in October 2025 after the FDA demanded a prohibitively large and costly trial design, this caps Vafseo's addressable market to the ~550K dialysis patients, leaving the larger non-dialysis CKD anemia population off limits
  • Akebia is not yet profitable; the legacy Auryxia franchise is under pressure from Teva's generic launch (March 2026), and Q1 2026 Auryxia revenue fell to $36.2M from $43.8M a year earlier, creating a revenue hole Vafseo must fill
  • Direct competition from GSK's Jesduvroq (daprodustat), the first oral HIF-PHI approved in the U.S. (Feb 2023) for dialysis patients, plus entrenched use of injectable ESAs (Epogen/Procrit) with decades of clinical data
● neutral
Impact
PhasePhase 2
Time to marketPraliciguat is in Phase 2 testing with estimated trial completion in January 2028. If successful, a Phase 3 program would be needed before any FDA submission, placing potential approval several years away at best.

praliciguat Updated Nov 7

What to watch

Praliciguat has no near-term binary catalyst. The Phase 2 FSGS trial is still enrolling with estimated completion in January 2028, and Akebia's Q3 2026 earnings call provided no data timeline for this asset. Watch for any future update on enrollment completion or a topline data readout timeline, but praliciguat is unlikely to be a meaningful stock-moving catalyst for AKBA in the next 12 months. The stock's near-term drivers are Vafseo commercial execution and the Nasdaq minimum bid price compliance situation.

Bull case
  • FSGS is a rare kidney disease with no FDA-approved therapies, representing an unmet medical need and potential orphan drug opportunity if praliciguat succeeds.
  • Praliciguat's mechanism (sGC stimulation) has a well-understood biological rationale for kidney protection, and prior Phase 1/2 studies showed an acceptable safety profile with no significant safety issues.
  • Akebia has a commercial infrastructure from Vafseo that could support a future FSGS launch, and the company is investing in the rare kidney disease pipeline with R&D spending increasing to $16.2 million in Q3 2026.
Bear case
  • Praliciguat previously failed to show clear clinical benefit in Phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and diabetic kidney disease, raising questions about its efficacy.
  • The Phase 2 FSGS trial is early-stage (just began enrolling in December 2025) with estimated completion not until January 2028, meaning no data catalyst for at least 12 months.
  • Akebia's market cap is only ~$111 million and the stock has fallen 80% in the past year, with the company facing a Nasdaq minimum bid price deficiency notice, creating financial overhang.

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
Mar 27, 2024VafseoApproval−8.5%−24.5%

Clinical trials

2 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
VadadustatVafseo Outcomes In-Center ExperiencePhase 3Completed2,116Sep 10, 2026
Erythropoiesis-Stimulating Agent (ESA)To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center HemodialysisPhase 3Completed353Aug 12, 2026